Comparative Studies of Calyculin A and Deslanoside on Rat Isolated Heart Inotropy and Their Underlying Mechanism
-
Graphical Abstract
-
Abstract
OBJECTIVE To investigate the inotropic effect and its underlying mechanism of calyculin A, a protein phosphatase (PP) inhibitor, compared to deslanoside, a digitalis positive inotropic agent. To provide inputs whether PP can be served as a potential therapeutic target to develop pharmacological inotropic agents in treatment of heart failure. METHODS Ex vivo study was used to record the effects of calyculin A and deslanoside on rat isolated contractilities. They were perfused to follow in order: normal perfusion solution→calyculin A(1, 4, 10 nmol/L) or normal perfusion solution→deslanoside(0.1, 1, 10 μmol/L). Ca2+ transients triggered by field stimulation and by caffeine (20 mmol/L) were measured to analyze the Ca2+ handling effects of calyculin A (100 nmol/L) and deslanoside (10 μmol/L). RESULTS Both calyculin A (1, 4, 10 nmol/L) and deslanoside (0.1, 1, 10 μmol/L) significantly increased the left ventricular developed pressure and the peak rate of rise of left pressure (P<0.05) and decreased the heart rate (P<0.05). Calyculin A (100 nmol/L) and deslanoside (10 μmol/L) significantly increased the amplitude of Ca2+ transient and shortened the Ca2+ transient duration at 50% full recovery level (P<0.05);Calyculin A also lowered diastolic cytoplasm Ca2+ concentration (P<0.05). Calyculin A (100 nmol/L) significantly increased the SERCA2a activity and combinational activities of Na+-Ca2+ exchanger (NCX) and plasma membrane Ca2+-ATPase (PMCA) (P<0.05); Deslanoside (10 μmol/L) only increased combinational activities of NCX and PMCA (P<0.05),resulting in lowering percentage of contribution of SERCA2a in Ca2+ reuptake phase of Ca2+ transient (P<0.05). CONCLUSION Calyculin A increases the amplitude of Ca2+ transient by enhancing activity of SERCA2a and combinational activities of NCX and PMCA, resulting in the positive inotropy and favorable relaxation. PP can be a potential therapeutic target to develop pharmacological inotropic agents in treatment of heart failure.
-
-